Brief: Hanall Biopharma Signs Licensing Agreement With Turn Biotechnologies
28/05/2024 12:03
May 28 (Reuters) - Hanall Biopharma Co Ltd 009420.KS :
* HANALL BIOPHARMA SIGNS LICENSING AGREEMENT WITH TURN
BIOTECHNOLOGIES TO DEVELOP NOVEL TREATMENTS FOR EYE AND EAR
DISEASES
* HANALL BIOPHARMA CO LTD - DEAL VALUE CAN EXCEED $300
MILLION USD
FOR INITIAL PRODUCT
Source text for Eikon: ID:nPn6gjPLBa
Further company coverage: 009420.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies